CL2007001457A1 - Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante. - Google Patents

Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.

Info

Publication number
CL2007001457A1
CL2007001457A1 CL2007001457A CL2007001457A CL2007001457A1 CL 2007001457 A1 CL2007001457 A1 CL 2007001457A1 CL 2007001457 A CL2007001457 A CL 2007001457A CL 2007001457 A CL2007001457 A CL 2007001457A CL 2007001457 A1 CL2007001457 A1 CL 2007001457A1
Authority
CL
Chile
Prior art keywords
pioglitazone
salt
useful
alkali metal
metal chloride
Prior art date
Application number
CL2007001457A
Other languages
English (en)
Spanish (es)
Inventor
Koyama Hiroyoshi
Okochi Kazuhiro
Shingaki Arisa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38294162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2007001457A1 publication Critical patent/CL2007001457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
CL2007001457A 2006-05-23 2007-05-22 Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante. CL2007001457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006143390 2006-05-23

Publications (1)

Publication Number Publication Date
CL2007001457A1 true CL2007001457A1 (es) 2008-01-04

Family

ID=38294162

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001457A CL2007001457A1 (es) 2006-05-23 2007-05-22 Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.

Country Status (14)

Country Link
US (1) US8865217B2 (enExample)
EP (1) EP2019669B1 (enExample)
JP (1) JP5162475B2 (enExample)
KR (1) KR20090024181A (enExample)
CN (2) CN103520158B (enExample)
AR (1) AR061070A1 (enExample)
AT (1) ATE534374T1 (enExample)
CA (1) CA2653786C (enExample)
CL (1) CL2007001457A1 (enExample)
ES (1) ES2377839T3 (enExample)
MY (1) MY146781A (enExample)
PE (1) PE20080180A1 (enExample)
TW (1) TWI407959B (enExample)
WO (1) WO2007136129A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US20120058205A1 (en) * 2009-03-04 2012-03-08 Walter Howard Peschel Compositions and treatment regimes for reducing inflammation, end-organ injury, and/or systemic endotoxemia
WO2010119851A1 (ja) * 2009-04-14 2010-10-21 ライオン株式会社 口腔内崩壊錠
US10071059B2 (en) * 2009-12-18 2018-09-11 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
JP5630902B2 (ja) * 2010-08-26 2014-11-26 沢井製薬株式会社 ゾルピデム酒石酸塩含有口腔内崩壊錠の製造方法
WO2012029838A1 (ja) * 2010-08-31 2012-03-08 協和発酵キリン株式会社 口腔内崩壊錠
JPWO2013129436A1 (ja) * 2012-02-29 2015-07-30 武田薬品工業株式会社 経口剤
AU2014236510A1 (en) 2013-03-14 2015-09-24 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP6574556B2 (ja) * 2014-08-27 2019-09-11 日東電工株式会社 口腔内フィルム状基剤及び製剤
CN104174022B (zh) * 2014-09-16 2018-10-16 过冬 一种吡格列酮的苦味抑制剂和包含吡格列酮的口服制剂
JP2018012697A (ja) * 2016-07-11 2018-01-25 大原薬品工業株式会社 口腔内崩壊時間が短縮された、塩を含有する錠剤
US20210386726A1 (en) * 2020-06-11 2021-12-16 Chang Gung University Method for inhibiting coronavirus infection and replication
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2809301B2 (ja) * 1993-12-09 1998-10-08 田辺製薬株式会社 苦味隠蔽された経口投与製剤
CN1059320C (zh) * 1994-04-07 2000-12-13 段永聚 一种无糖型草珊瑚含片
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US7135485B2 (en) * 2001-09-28 2006-11-14 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
JP2003183162A (ja) * 2001-12-17 2003-07-03 Sumitomo Pharmaceut Co Ltd シメチジン経口製剤
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
WO2003075919A1 (fr) 2002-03-14 2003-09-18 Daiichi Suntory Pharma Co.,Ltd. Comprime contenant du chlorhydrate de pilsicainide (voie seche)
US20050131027A1 (en) * 2002-03-21 2005-06-16 Guy Samburski Fine particle size pioglitazone
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
KR20070011497A (ko) * 2004-05-11 2007-01-24 산텐 세이야꾸 가부시키가이샤 각결막 장해 치료제
KR100843508B1 (ko) * 2004-09-29 2008-07-04 모리나가 뉴교 가부시키가이샤 고혈당 개선용 의약
HRP20160679T1 (hr) 2005-12-22 2016-07-15 Takeda Pharmaceutical Company Limited Kruti pripravak koji sadrži senzibilizator inzulina
JP5276991B2 (ja) 2006-04-27 2013-08-28 武田薬品工業株式会社 固形製剤

Also Published As

Publication number Publication date
CN101489538B (zh) 2014-01-08
ATE534374T1 (de) 2011-12-15
EP2019669A1 (en) 2009-02-04
AR061070A1 (es) 2008-07-30
JP2009538268A (ja) 2009-11-05
TWI407959B (zh) 2013-09-11
TW200806332A (en) 2008-02-01
KR20090024181A (ko) 2009-03-06
CA2653786C (en) 2014-09-23
WO2007136129A1 (en) 2007-11-29
PE20080180A1 (es) 2008-04-22
CN103520158A (zh) 2014-01-22
CN101489538A (zh) 2009-07-22
EP2019669B1 (en) 2011-11-23
MY146781A (en) 2012-09-28
ES2377839T3 (es) 2012-04-02
JP5162475B2 (ja) 2013-03-13
CN103520158B (zh) 2016-02-03
US20100136122A1 (en) 2010-06-03
CA2653786A1 (en) 2007-11-29
HK1129566A1 (en) 2009-12-04
US8865217B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
CL2007001457A1 (es) Preparacion oral que comprende pioglitazona o una sal de la misma y un cloruro de metal alcalino, util como hipoglicemiante.
BRPI0923823A2 (pt) Agente de colaboração.
ATE501210T1 (de) Titandioxid enthaltendes komposit
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
BRPI0911610A2 (pt) sincronização de máquina virtual e ciclos de vida de aplicação.
EA200870357A1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
BRPI0815773A2 (pt) composto, e, medicamento.
CR20110121A (es) Compuestos insecticidas
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EP1897265A4 (en) SAFE INSTANT MESSAGING
EP2356989A4 (en) STABLE TABLET WITH 4,5-EPOXYMORPHINAN DERIVATIVE
AR053613A1 (es) Combinacion de compuestos activos fungicidas
FR2900034B1 (fr) Poudrier.
BRPI0716049A2 (pt) dispersÕes de nanourÉias, contendo substÂncias ativas
NL1032915A1 (nl) Katheterpunt.
UA107068C2 (xx) Гербіцидна комбінація, що містить дифлуфенікан та інгібітор алс
WO2008145475A8 (en) Oral care composition
GT200700016S (es) Envase
CR8839S (es) Paquete particularmente util para articulos de fumador
BRPI0815562A2 (pt) Soluções farmacêuticas orais contendo telbivudina.
ITTO20060659A1 (it) Arresto di fondo corsa per una cerniera lampo, e cerniera lampo comprendente un tale arresto di fondo corsa.
FI20055288A0 (fi) Yksittäinen sanomanvälitys
ITMO20050182A1 (it) Ago per biopsia dei tessuti molli.